Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 20/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4184953 | 0.92 | TRPV1 (0.85) | TRPV1 | |
| SCHEMBL4191503 | 0.92 | TRPV1 (0.84) | TRPV1 | |
| SCHEMBL5633032 | 0.92 | TRPV1 (0.85) | TRPV1 | |
| SCHEMBL5634429 | 0.91 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL5633175 | 0.91 | TRPV1 (0.81) | TRPV1 | |
| SCHEMBL5633652 | 0.90 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL4200601 | 0.90 | TRPV1 (1.00) | TRPV1 | |
| Hydrochloric Acid SCHEMBL5632530 | 0.90 | TRPV1 (0.98) | TRPV1 | |
| SCHEMBL5634847 | 0.88 | TRPV1 (0.88) | TRPV1 | |
| SCHEMBL4186758 | 0.88 | TRPV1 (1.00) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738649-B2 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-08-22 | — | — | US | claimed |
| US-20160318942-A1 | TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | US | claimed |
| US-20140135311-A1 | TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-15 | — | — | US | claimed |
| US-20070225275-A1 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-27 | — | — | US | claimed |
| US-9738649-B2 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-08-22 | — | — | US | disclosed |
| US-20160318942-A1 | TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | US | disclosed |
| US-9422293-B2 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-08-23 | — | — | US | disclosed |
| US-20140135311-A1 | TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-15 | — | — | US | disclosed |
| EP-2024368-B1 | 6,7,8,9-TETRAHYDRO-5H-PYRIMIDO[4,5-D]AZEPIN-4-YL]-AMINE DERIVATIVES AS MODULATORS OF TRPV1 FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-30 | — | — | EP | disclosed |
| US-8673895-B2 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-18 | — | — | US | disclosed |
| US-20070225275-A1 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318942-A1 | TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885 |
| US-20140135311-A1 | TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885 |
| US-20070225275-A1 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.